These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 1,4-Dihydropyridine: A Dependable Heterocyclic Ring with the Promising and the Most Anticipable Therapeutic Effects. Mishra AP; Bajpai A; Rai AK Mini Rev Med Chem; 2019; 19(15):1219-1254. PubMed ID: 31735158 [TBL] [Abstract][Full Text] [Related]
5. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): action in ion channels and GPCRs. Ioan P; Carosati E; Micucci M; Cruciani G; Broccatelli F; Zhorov BS; Chiarini A; Budriesi R Curr Med Chem; 2011; 18(32):4901-22. PubMed ID: 22050742 [TBL] [Abstract][Full Text] [Related]
6. A genetic screen for dihydropyridine (DHP)-resistant worms reveals new residues required for DHP-blockage of mammalian calcium channels. Kwok TC; Hui K; Kostelecki W; Ricker N; Selman G; Feng ZP; Roy PJ PLoS Genet; 2008 May; 4(5):e1000067. PubMed ID: 18464914 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Ogihara T; Kano T; Kakinuma C Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509 [TBL] [Abstract][Full Text] [Related]
8. Vascular effects of calcium channel antagonists: new evidence. Richard S Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057 [TBL] [Abstract][Full Text] [Related]
9. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815 [TBL] [Abstract][Full Text] [Related]
10. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195 [TBL] [Abstract][Full Text] [Related]
11. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities. Liang JC; Yeh JL; Wang CS; Liou SF; Tsai CH; Chen IJ Bioorg Med Chem; 2002 Mar; 10(3):719-30. PubMed ID: 11814861 [TBL] [Abstract][Full Text] [Related]
12. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential]. Żorniak M; Mitręga K; Krzemiński TF Kardiol Pol; 2011; 69 Suppl 3():100-3. PubMed ID: 22125212 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Takahashi D; Oyunzul L; Onoue S; Ito Y; Uchida S; Simsek R; Gunduz MG; Safak C; Yamada S Biol Pharm Bull; 2008 Mar; 31(3):473-9. PubMed ID: 18310913 [TBL] [Abstract][Full Text] [Related]
14. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Paris D; Bachmeier C; Patel N; Quadros A; Volmar CH; Laporte V; Ganey J; Beaulieu-Abdelahad D; Ait-Ghezala G; Crawford F; Mullan MJ Mol Med; 2011; 17(3-4):149-62. PubMed ID: 21170472 [TBL] [Abstract][Full Text] [Related]